Context Therapeutics (NASDAQ:CNTX) Posts Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Posted by Francis Steltz on Aug 6th, 2026

Context Therapeutics (NASDAQ:CNTX – Get Free Report) released its earnings results on Wednesday. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.06), FiscalAI reports.

Context Therapeutics Price Performance

Shares of Context Therapeutics stock traded down $0.17 on Thursday, hitting $0.53. The company had a trading volume of 1,700,192 shares, compared to its average volume of 1,812,359. The stock has a 50-day moving average of $0.95 and a 200-day moving average of $1.93. Context Therapeutics has a twelve month low of $0.49 and a twelve month high of $3.62. The firm has a market capitalization of $48.24 million, a P/E ratio of -1.25 and a beta of 1.74.

Institutional Trading of Context Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Millennium Management LLC acquired a new position in shares of Context Therapeutics during the fourth quarter worth about $3,824,000. Marshall Wace LLP lifted its stake in Context Therapeutics by 7,153.7% in the 4th quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock valued at $3,812,000 after acquiring an additional 2,557,448 shares in the last quarter. Vanguard Group Inc. lifted its stake in Context Therapeutics by 4.0% in the 3rd quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock valued at $3,387,000 after acquiring an additional 134,449 shares in the last quarter. XTX Topco Ltd boosted its position in Context Therapeutics by 858.8% during the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock worth $149,000 after acquiring an additional 91,008 shares during the last quarter. Finally, State Street Corp boosted its position in Context Therapeutics by 8.5% during the 4th quarter. State Street Corp now owns 165,607 shares of the company’s stock worth $243,000 after acquiring an additional 13,000 shares during the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Analyst Ratings Changes

CNTX has been the topic of several recent research reports. Maxim Group reduced their target price on shares of Context Therapeutics from $8.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, June 16th. Wall Street Zen lowered shares of Context Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, July 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Context Therapeutics in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $6.17.

Read Our Latest Stock Analysis on Context Therapeutics

Context Therapeutics Company Profile

(Get Free Report)

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.